Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

NCT06439836 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

27

Enrollment

NIH

Sponsor class

Conditions

Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Interventions

PROCEDURE: Biopsy Procedure
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
BIOLOGICAL: Emavusertib
PROCEDURE: Magnetic Resonance Imaging
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)